Your browser doesn't support javascript.
loading
InsulinAPP application protocol for the inpatient management of type 2 diabetes on a hospitalist-managed ward: a retrospective study.
Toyoshima, Marcos Tadashi Kakitani; Brandes, Pedro Henrique Ribeiro; da Paz Lauterbach, Gerhard; Moraes, Jéssica Ribeiro Andrade; de Paiva, Edison Ferreira; Umpierrez, Guillermo E; Nery, Marcia; Kondo, Rodrigo Hidd.
Afiliación
  • Toyoshima MTK; Serviço de Onco-endocrinologia, Instituto do Câncer do Estado de São Paulo Octávio Frias de Oliveira, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil, marcos.tadashi@hc.fm.usp.br.
  • Brandes PHR; Serviço de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • da Paz Lauterbach G; Serviço de Medicina Hospitalar, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Moraes JRA; Serviço de Medicina Hospitalar, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • de Paiva EF; Serviço de Medicina Hospitalar, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Umpierrez GE; Serviço de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Nery M; Serviço de Medicina Hospitalar, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Kondo RH; Serviço de Medicina Hospitalar, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
Arch Endocrinol Metab ; 66(4): 498-505, 2022.
Article en En | MEDLINE | ID: mdl-35758838
ABSTRACT

Introduction:

We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital. Subjects and

methods:

We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in bolus-correction or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were evaluated.

Results:

A total of 147 T2D individuals (23% medicine and 77% surgery) were included (mean age 62.3 ± 12.7 years, HbA1c 8.3 ± 3.0%). The initial insulin regimen was 50% bolus-correction, 47% basal-bolus and 3% with sliding scale insulin. During hospitalization, 71% patients required a bolus-basal regimen. In the first 10 days of the protocol, 71% BG measurements were between 70-180 mg/dL and 26% patients experienced one or more episodes of hypoglycemia < 70 mg/dL, and 5% with BG < 54 mg/dL.

Conclusion:

The results of this retrospective study indicate the InsulinAPP application using human insulin formulations was effective and safe for the management of hyperglycemia on a hospitalist-managed ward, with more than 70% BG measurements within the therapeutic range and a low rate of hypoglycemia.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Médicos Hospitalarios / Diabetes Mellitus Tipo 2 / Hipoglucemia Tipo de estudio: Guideline / Observational_studies Límite: Aged / Humans / Middle aged Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Médicos Hospitalarios / Diabetes Mellitus Tipo 2 / Hipoglucemia Tipo de estudio: Guideline / Observational_studies Límite: Aged / Humans / Middle aged Idioma: En Año: 2022 Tipo del documento: Article